Doubts About Stroma-Targeting Agents in Pancreatic Cancer Doubts About Stroma-Targeting Agents in Pancreatic Cancer
Adding pegvorhyaluronidase alfa to treatment with nab-paclitaxel and gemcitabine did not improve survival in adults with previously untreated metastatic pancreatic ductal adenocarcinoma in a phase 3 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Is Adenocarcinoma an Aggressive Cancer?
Title: Is Adenocarcinoma an Aggressive Cancer?Category: Diseases and ConditionsCreated: 7/30/2020 12:00:00 AMLast Editorial Review: 7/30/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 30, 2020 Category: Cancer & Oncology Source Type: news

Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer
Prospective study shows increased risk for esophageal, gastric adenocarcinoma in two large cohorts (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 21, 2020 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Infections, Internal Medicine, Oncology, ENT, Journal, Source Type: news

Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer
TUESDAY, July 21, 2020 -- Periodontal disease and tooth loss, indicative of oral microbial dysbiosis, are associated with esophageal and gastric adenocarcinoma, according to a research letter published online July 20 in Gut. Chun-Han Lo, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 21, 2020 Category: Pharmaceuticals Source Type: news

Scientists reveal comprehensive proteomic map of human lung adenocarcinoma
(Chinese Academy of Sciences Headquarters) A team of Chinese scientists from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, National Center for Protein Sciences (Beijing), National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Shanghai Jiao Tong University, recently reported a comprehensive proteomic analysis based on 103 Chinese patients with lung adenocarcinoma (LUAD), a leading cause of death among all types of cancer worldwide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2020 Category: Cancer & Oncology Source Type: news

New guideline: Don't routinely screen for EAC in patients with chronic GERD
(Canadian Medical Association Journal) A new guideline from the Canadian Task Force on Preventive Health Care, based on a rigorous systematic review of the latest evidence, found no benefit of routine screening for esophageal adenocarcinoma (EAC) and precursor conditions (Barrett esophagus and dysplasia) in patients with chronic gastroesophageal reflux disease (GERD). The guideline, published in CMAJ (Canadian Medical Association Journal), recommends physicians in Canada continue current practice to not screen routinely http://www.cmaj.ca/lookup/doi/10.1503/cmaj.190814. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 6, 2020 Category: Cancer & Oncology Source Type: news

Primary Gastric Adenocarcinoma Cells Have Distinct Gene-Expression Profiles Primary Gastric Adenocarcinoma Cells Have Distinct Gene-Expression Profiles
Primary gastric adenocarcinoma cells can be divided into five subgroups based on their gene-expression profiles, researchers in China report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oncotarget: The role of EGFR mutations in predicting recurrence in lung adenocarcinoma
(Impact Journals LLC) Volume 11, Issue 22 of @Oncotarget reported that while lobectomy can improve mortality in this group, about 30 55% of patients will experience disease recurrence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 10, 2020 Category: Cancer & Oncology Source Type: news

AI can aid radiologists in detecting pancreatic cancer
An artificial intelligence (AI) algorithm helped radiologists from Taiwan improve...Read more on AuntMinnie.comRelated Reading: ASTRO updates guidance on pancreatic cancer CT perfusion shows promising utility in cancer treatment Cinematic rendering tops CT to visualize patient anatomy Can radiomics detect pancreatic ductal adenocarcinoma? Case report: Necrotizing pancreatitis after SAE (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 1, 2020 Category: Radiology Source Type: news

Updated data demonstrate Roche ’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer
Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented updated data from the pivotal phase III ALEX study, showing an increased five-year survival rate with Alecensa ® (alectinib), compared with crizotinib, in people living with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). These data confirm the longer-term efficacy of Alecensa already demonstrated across three phase III clinical trials. Full findings were presented at the ASCO2 0 Virtual Scientific Programme, on 29 May 2020.“These data further support Alecensa as the standard of care for people with metastatic AL...
Source: Roche Media News - May 29, 2020 Category: Pharmaceuticals Source Type: news

Trastuzumab combined with trimodality treatment does not improve outcomes for patients
(NRG Oncology) Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2020 Category: Cancer & Oncology Source Type: news

CSIC researchers use whole living cells as 'templates' to seek for bioactive molecules
(Spanish National Research Council (CSIC)) A study performed by researchers at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) from the Spanish National Research Council (CSIC) pioneers the use of whole living cells (human lung adenocarcinoma) in dynamic combinatorial chemistry systems. This research, published in the journal Angewandte Chemie International Edition, proposes a new methodology to discover new bioactive molecules in a realistic biological medium. This methodology could help in the future to develop methods to differentiate healthy versus cancer cells, or to protect the extracellular matrix agai...
Source: EurekAlert! - Biology - May 27, 2020 Category: Biology Source Type: news

Platinum Therapy May Up Survival in Pancreatic Cancer With DNA Repair Defects
TUESDAY, May 26, 2020 -- For patients with advanced-stage pancreatic ductal adenocarcinoma (PDAC), those with homologous recombination deficiency (HRD) have improved survival with first-line (1L) platinum treatment, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2020 Category: Pharmaceuticals Source Type: news

Why pancreatic ductal adenocarcinoma is so lethal
(Cold Spring Harbor Laboratory) Pancreatic ductal carcinoma is a fast growing and invasive cancer, and now scientists understand the molecular dance that makes it so deadly. CSHL researchers discovered factors that allow a pancreatic cell to lose its identity, turn into an aggressive cancer cell, and recruit surrounding cells to help it invade more effectively. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2020 Category: Cancer & Oncology Source Type: news

Esophageal, Gastric Adenocarcinomas After H. pylori Infection Esophageal, Gastric Adenocarcinomas After H. pylori Infection
Does treatment and eradication of H pylori reduce the risk of future esophageal and proximal gastric cancer?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Professionals Analyze Pathology Following lung Lobectomies for Adenocarcinoma
Researchers examined the pathology of early-phase COVID-19 pneumonia in two older patients who were admitted to the hospital for adenocarcinoma procedures, but did not exhibit COVID-19 symptoms at the time of these procedures. (Source: CancerNetwork)
Source: CancerNetwork - April 14, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Cysteine depletion induces pancreatic tumor ferroptosis in mice
Ferroptosis is a form of cell death that results from the catastrophic accumulation of lipid reactive oxygen species (ROS). Oncogenic signaling elevates lipid ROS production in many tumor types and is counteracted by metabolites that are derived from the amino acid cysteine. In this work, we show that the import of oxidized cysteine (cystine) via system xC– is a critical dependency of pancreatic ductal adenocarcinoma (PDAC), which is a leading cause of cancer mortality. PDAC cells used cysteine to synthesize glutathione and coenzyme A, which, together, down-regulated ferroptosis. Studying genetically engineered mice,...
Source: ScienceNOW - April 2, 2020 Category: Science Authors: Badgley, M. A., Kremer, D. M., Maurer, H. C., DelGiorno, K. E., Lee, H.-J., Purohit, V., Sagalovskiy, I. R., Ma, A., Kapilian, J., Firl, C. E. M., Decker, A. R., Sastra, S. A., Palermo, C. F., Andrade, L. R., Sajjakulnukit, P., Zhang, L., Tolstyka, Z. P., Tags: Cell Biology, Medicine, Diseases reports Source Type: news

10-Year Outcomes Similar for H-IMRT, C-IMRT in Prostate Cancer
MONDAY, March 23, 2020 -- For men with intermediate- and high-risk prostate adenocarcinoma, 10-year outcomes are similar with conventionally fractionated intensity-modulated radiation therapy (C-IMRT) or moderate hypofractionated IMRT (H-IMRT),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2020 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.[1...
Source: Johnson and Johnson - March 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pancreatic Cancer Patients May Harbor Treatable Germline Mutations Pancreatic Cancer Patients May Harbor Treatable Germline Mutations
Germline mutations commonly found in individuals with pancreatic ductal adenocarcinoma (PDAC) may be treatable and should be identified as soon as possible, a comprehensive review suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 3, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis
Non–small cell lung cancer (NSCLC) is often characterized by mutually exclusive mutations in the epidermal growth factor receptor (EGFR) or the guanosine triphosphatase KRAS. We hypothesized that blocking EGFR palmitoylation, previously shown to inhibit EGFR activity, might alter downstream signaling in the KRAS-mutant setting. Here, we found that blocking EGFR palmitoylation, by either knocking down the palmitoyltransferase DHHC20 or expressing a palmitoylation-resistant EGFR mutant, reduced activation of the kinase PI3K, the abundance of the transcription factor MYC, and the proliferation of cells in culture, as we...
Source: Signal Transduction Knowledge Environment - March 3, 2020 Category: Science Authors: Kharbanda, A., Walter, D. M., Gudiel, A. A., Schek, N., Feldser, D. M., Witze, E. S. Tags: STKE Research Articles Source Type: news

HPV Biomarkers Linked to Improved Survival With Esophageal Dysplasia, Adenocarcinoma HPV Biomarkers Linked to Improved Survival With Esophageal Dysplasia, Adenocarcinoma
Human papillomavirus (HPV) positivity and HPV biomarkers are associated with improved survival in adults with Barrett high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC), according to a new study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 21, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

When a Promising Trial Fails, It Can Feel Personal When a Promising Trial Fails, It Can Feel Personal
Dr Mark Lewis shares how even with disappointing trial results, he remains hopeful that continuing research will craft a better present and future for our patients with pancreatic adenocarcinoma.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Overall survival in patients with lung adenocarcinoma harboring 'niche' mutations
(Impact Journals LLC) Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET.The multivariable analysis showed that:Niche mutations had higher mortality than EGFR mutationsKRAS mutations had higher mortality than EGFR mutations, andNiche mutations presented similar mortality to KRAS mutations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 4, 2020 Category: Cancer & Oncology Source Type: news

Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma
This case of severe grade V thrombocytopenia caused by nivolumab highlights the need for clinicians to be aware of this potential adverse effect of immune-checkpoint inhibitors.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 14, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) (Source: World Pharma News)
Source: World Pharma News - December 31, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma
FDA approved olaparib (LYNPARZA ®, AstraZeneca) for maintenance treatment of patients with gBRCAm metastatic pancreatic adenocarcinoma, as detected by an FDA-approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 30, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves First PARP Inhibitor as Frontline Maintenance in Pancreatic Cancer
The FDA approved olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - December 30, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
AstraZeneca and MSD Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 5 to recommend Lynparza (olaparib) as a 1st-line maintenance monotherapy for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer), whose disease has not progressed following 1st-line platinum-based chemotherapy. (Source: World Pharma News)
Source: World Pharma News - December 18, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

PET/CT plays role in lung adenocarcinoma management
(American Roentgen Ray Society) According to an article published in the American Journal of Roentgenology (AJR), FDG PET, combined with high-resolution CT, has value for predicting invasive histopathologic subtypes, but there was no significance for predicting invasive growth patterns of early lung adenocarcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 16, 2019 Category: International Medicine & Public Health Source Type: news

Chaga Mushroom (Inonotus obliquus) inhibits growth of both lung adenocarcinoma (A549) cells and Aspergillus fumigatus
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 11, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Modulation of proliferation factors in lung adenocarcinoma with an analysis of the transcriptional consequences of genomic EGFR activation
(Impact Journals LLC) Molecular subtypes based on copy number, DNA methylation, and mRNA expression had variable proliferation levels, the highest correlating with decreased survival. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2019 Category: International Medicine & Public Health Source Type: news

Virtual biopsy accurately diagnoses pancreatic cysts
A new "virtual biopsy" using ultrasound guidance allows doctors to definitively...Read more on AuntMinnie.comRelated Reading: USPSTF again dismisses pancreatic cancer screening New class of radiotracers targets many cancer types Can radiomics detect pancreatic ductal adenocarcinoma? Optical imaging finds small tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 6, 2019 Category: Radiology Source Type: news

Biocon, Mylan launch cancer drug in US market
Ogivri, available in a 420mg multi-dose vial and a 150mg single-dose vial, will be used for treatment of all types of breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 2, 2019 Category: Pharmaceuticals Source Type: news

CT radiomics predicts lung cancer immunotherapy response
A new radiomics technique can determine which lung cancer patients will benefit...Read more on AuntMinnie.comRelated Reading: AI, radiomics predict prostate cancer aggressiveness CT radiomics uses immunohistology to detect thyroid cancer AI can improve reproducibility of radiomics in CT Can radiomics detect pancreatic ductal adenocarcinoma? AI, radiomics can help predict chemotherapy response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 26, 2019 Category: Radiology Source Type: news

How a 73-year-old heavy smoker's 'velvety' palms turned out to be a sign of lung cancer
The unnamed woman, of São Paulo, Brazil, had 'tripe palms' - often the sign of an underlying cancer. Tests revealed the woman had adenocarcinoma and she had treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - November 18, 2019 Category: Consumer Health News Source Type: news

Protein could offer therapeutic target for pancreatic cancer
A protein that drives growth of pancreatic cancer, and which could be a target for new treatments, has been identified by researchers at the Crick. The study, published in Nature Cell Biology, looked into the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma. This is an aggressive cancer that develops from secretory and tubular cells of the pancreas. (Source: World Pharma News)
Source: World Pharma News - November 12, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

TAS-102 Prolongs Survival in Metastatic Gastric, GEJ Adenocarcinoma
TAS-102 improved overall survival, compared with placebo, in patients with metastatic gastric or gastroesophageal junction (GEJ) cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 15, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Pancreatic Cancer: What the ESPAC-4 Randomized Adjuvant Chemotherapy Trial Tells Us
Researchers examine patterns of recurrence after resection of pancreatic ductal adenocarcinoma.   (Source: CancerNetwork)
Source: CancerNetwork - October 11, 2019 Category: Cancer & Oncology Authors: Leanne Marcello, MS Source Type: news

Prognostic Value of Intraoperative Bile Spillage in Gallbladder Adenocarcinoma
Intraoperative bile spillage might serve as a prognostic tool for gall bladder cancer.   (Source: CancerNetwork)
Source: CancerNetwork - October 3, 2019 Category: Cancer & Oncology Authors: Leanne Marcello, MS Source Type: news

Fungal invasion of pancreas creates cancer risk
Certain fungi move from the gut to the pancreas, expand their population more than a thousand-fold, and encourage pancreatic cancer growth, a new study finds. Published online in Nature October 2, the study is the first to offer strong evidence that the mycobiome - the local mix of fungal species in the pancreas - can trigger changes that turn normal cells into pancreatic ductal adenocarcinoma or PDA. (Source: World Pharma News)
Source: World Pharma News - October 2, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Combination therapy shows promise against fast-growing lung cancer
A trio of genetic pathway inhibiting compounds shrunk lung tumors in mice and human cancer cells caused by a mutation in the KRAS gene, suggesting a new treatment method for adenocarcinomas. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 19, 2019 Category: Consumer Health News Source Type: news

Study finds new way to make chemotherapy more effective against pancreatic cancer
ROCHESTER, Minn. -- Pancreatic adenocarcinoma (PDAC) is a lethal malignancy that most often is resistant to chemotherapy. Researchers have been searching for ways to increase the sensitivity of the tumors to cancer-fighting drugs. A Mayo Clinic-led study published today opens a promising new front in that battle. Using patient cell lines and tumor-bearing models, researchers [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 18, 2019 Category: Databases & Libraries Source Type: news

Can CT-Based Biomarkers Help Guide Pancreatic Cancer Therapy?
An imaging-based biomarker may offer a way to personalize treatment for pancreatic ductal adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - September 9, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

What Are Treatment Options After Progression in PDL-1 –Positive Metastatic Lung Adenocarcinoma after Chemo/IO?
What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1 –positive lung adenocarcinoma with no sensitizing mutations? (Source: CancerNetwork)
Source: CancerNetwork - August 23, 2019 Category: Cancer & Oncology Authors: Yuly A. Remolina-Bonilla, MD, Raul R. Trejo-Rosales, MD, Bruno Saldivar-Oviedo, Alejandro Gabutti, MD, Maria T. Bourlon MD, MS Source Type: news

Can Immunotherapy Play a Role in Pancreatic Ductal Adenocarcinoma?
A combination of  durvalumab and tremelimumab was tested on patients with metastatic pancreatic ductal adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - August 13, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

USPSTF Reaffirms Recs Against Screening for Pancreatic Cancer
TUESDAY, Aug. 6, 2019 -- The U.S. Preventive Services Task Force (USPSTF) recommends against screening for pancreatic adenocarcinoma as the potential benefits do not outweigh the potential harms. These recommendations form the basis of a final... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 6, 2019 Category: Pharmaceuticals Source Type: news

Discovery of distinct lung cancer pathways may lead to more targeted treatments
JACKSONVILLE, Fla. -- Known for its poor prognosis, lung adenocarcinoma is the most common type of lung cancer, responsible for about 4 of 10 diagnoses, according to the National Cancer Institute. Researchers on Mayo Clinic's Florida campus can now distinguish between two pathways where this deadly cancer can develop. They say their discovery could help future patients. [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 1, 2019 Category: Databases & Libraries Source Type: news

New Combination Shows Early Promise in Gastric Cancer
Patients responded relatively well to the phase I trial testing a new treatment for several malignancies, including gastric and gastroesophageal junction adenocarcinomas. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
Stabilization of the MYC oncoprotein by KRAS signaling critically promotes the growth of pancreatic ductal adenocarcinoma (PDAC). Thus, understanding how MYC protein stability is regulated may lead to effective therapies. Here, we used a previously developed, flow cytometry–based assay that screened a library of>800 protein kinase inhibitors and identified compounds that promoted either the stability or degradation of MYC in a KRAS-mutant PDAC cell line. We validated compounds that stabilized or destabilized MYC and then focused on one compound, UNC10112785, that induced the substantial loss of MYC protein in both...
Source: Signal Transduction Knowledge Environment - July 16, 2019 Category: Science Authors: Blake, D. R., Vaseva, A. V., Hodge, R. G., Kline, M. P., Gilbert, T. S. K., Tyagi, V., Huang, D., Whiten, G. C., Larson, J. E., Wang, X., Pearce, K. H., Herring, L. E., Graves, L. M., Frye, S. V., Emanuele, M. J., Cox, A. D., Der, C. J. Tags: STKE Research Articles Source Type: news